The awarding ceremony of "Golden Horse Award of China Stock Market 2020" sponsored by Securities Daily was held in Beijing on the evening of 65438+February 1 1, and Yiling Pharmaceutical won the honorary title of "Golden Horse Award of the Most Artisan Listed Company".
It is understood that the "most craftsman-oriented listed company" award is to commend listed companies whose net profit has continued to grow in the past three years and has exemplary significance in the industry. The shortlisted criteria include: artisan spirit is of great significance to the development of enterprises; Craftsman spirit has traceability and inheritance; The craftsman spirit has been recognized by the industry and has a demonstration role.
Yiling Pharmaceutical Co., Ltd. is a top Chinese medicine 10 enterprise in China, a top 20 listed companies in China and a top 500 listed companies in China. Since the establishment of 1992, Yiling Pharmaceutical has been adhering to the corporate purpose of "inheriting and innovating for the benefit of mankind", adhering to the market-led and technology-driven innovation development strategy, and established a unique operation mode of "theory-clinic-scientific research-industry-teaching" and an innovative technology system for new drug research and development oriented to the theoretical innovation of collateral diseases in traditional Chinese medicine. After 28 years of development, it has formed three major business sectors: modern Chinese medicine, chemical pharmacy and health industry.
The innovative research on collateral disease theory is a model of traditional Chinese medicine inheritance and innovation in recent years, and it is also the ingenious achievement of Yiling Pharmaceutical. Under the guidance of collateral disease theory, Yiling Pharmaceutical Co., Ltd. has developed more than ten kinds of innovative patented traditional Chinese medicines, including Lianhua Qingwen Capsule (granules), Tongxinluo Capsule, Shen Song Yangxin Capsule, Qiliqiangxin Capsule, Yangzhengxiaoji Capsule, Jinlida Granule, Lianhua Qingke Tablet and Bazi Bushen Capsule, among which 7 kinds are listed in the national medical insurance catalogue and 5 kinds are listed in the national essential drugs catalogue, covering respiratory system, kidney and other fields. In 20 19, the project "Construction of TCM theory of venation and its guidance for prevention and treatment of microangiopathy" hosted by Yiling Institute of Medicine won the first prize of national scientific and technological progress, which is also the only highest prize in the field of medicine and health.
In the first three quarters of 2020, Yiling Pharmaceutical achieved a total operating income of 6.447 billion yuan, a year-on-year increase of 48.438+0%; The net profit attributable to shareholders of the parent company was 65,438+0,065,438+0.6 billion yuan, up 76.74% year-on-year. The total operating income and net profit attributable to the parent company both exceeded the whole year of 2065,438+09. In recent years, Yiling Pharmaceutical's investment in R&D has continued to increase. The company's third quarterly report shows that in the first three quarters of this year, Yiling Pharmaceutical spent 390 million yuan on R&D, up 48.49% year-on-year. The continuous investment of R&D has helped Yiling Pharmaceutical to improve its quality and quantity.
At the same time, the internationalization of traditional Chinese medicine in Yiling Pharmaceutical is also accelerating. According to the company's announcement, Lianhua Qingwen has been listed in nearly 20 countries and regions such as Canada, Russia, the Philippines and Kuwait. While contributing to the prevention and control of overseas epidemics, it has further opened up the growth space of the company's overseas business. The data shows that, driven by the overseas sales of Lianhua Qingwen Capsule and other factors, Yiling Pharmaceutical achieved revenue of 654.38+0.24 billion yuan in foreign regions in the first half of the year, an increase of over 20 times compared with the same period of last year.